Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novacyt ( (FR:ALNOV) ) has issued an announcement.
Novacyt’s subsidiary Yourgene Health UK has secured the South West London Procurement Partnership tender to provide non-invasive prenatal testing services to St George’s University Hospitals NHS Foundation Trust using its IONA Nx NIPT Workflow, following a competitive process. The new contract, which starts in December 2025 for an initial two-year term with an option to extend for another two years, renews a long-standing relationship under which St George’s has deployed the IONA-based SAFE test to serve roughly one third of England’s NHS maternity population and private patients, reinforcing Novacyt’s position in the expanding prenatal screening market and supporting its double-digit growth ambitions through continued operational scale and closer integration with UK genomic services.
More about Novacyt
Novacyt S.A. is an international molecular diagnostics group focused on genomic medicine, developing, manufacturing and commercialising molecular assays, instrumentation and end-to-end workflows across human health, animal health and environmental sectors. The business operates through clinical diagnostics, DNA instrumentation platforms and research-use-only services, offering solutions such as non-invasive prenatal testing, precision medicine assays, infectious disease panels and genomic sequencing support, and maintains a commercial footprint in more than 65 countries from its headquarters in France and offices in the UK, Singapore, the US and Canada.
See more insights into ALNOV stock on TipRanks’ Stock Analysis page.